Avecho Biotechnology Limited, a biotechnology company, develops, produces, sells, and licenses products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, animal health, and nutrition industries in Australia and internationally.
Avecho Biotechnology Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.018|
|52 Week High||AU$0.01|
|52 Week Low||AU$0.045|
|1 Month Change||0%|
|3 Month Change||-5.26%|
|1 Year Change||80.00%|
|3 Year Change||-35.71%|
|5 Year Change||-43.75%|
|Change since IPO||-96.25%|
Recent News & Updates
We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. Indeed, Avecho Biotechnology ( ASX:AVE...
We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|AVE||AU Pharmaceuticals||AU Market|
Return vs Industry: AVE exceeded the Australian Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: AVE exceeded the Australian Market which returned 24.4% over the past year.
Stable Share Price: AVE is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: AVE's weekly volatility has decreased from 25% to 13% over the past year, but is still higher than 75% of Australian stocks.
About the Company
Avecho Biotechnology Limited, a biotechnology company, develops, produces, sells, and licenses products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, animal health, and nutrition industries in Australia and internationally. The company operates through Production, Human Health, and Other segments. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulations; and develops TPM/Oxymorphone and TPM/Oxycodone.
Avecho Biotechnology Fundamentals Summary
|AVE fundamental statistics|
Is AVE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AVE income statement (TTM)|
|Cost of Revenue||AU$195.39k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0019|
|Net Profit Margin||-771.69%|
How did AVE perform over the long term?See historical performance and comparison
Is Avecho Biotechnology undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AVE's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AVE's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AVE is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.
PE vs Market: AVE is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AVE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AVE is overvalued based on its PB Ratio (5.6x) compared to the AU Pharmaceuticals industry average (3.7x).
How is Avecho Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Avecho Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Avecho Biotechnology performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AVE is currently unprofitable.
Growing Profit Margin: AVE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AVE is unprofitable, but has reduced losses over the past 5 years at a rate of 53.1% per year.
Accelerating Growth: Unable to compare AVE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).
Return on Equity
High ROE: AVE has a negative Return on Equity (-58.8%), as it is currently unprofitable.
How is Avecho Biotechnology's financial position?
Financial Position Analysis
Short Term Liabilities: AVE's short term assets (A$6.1M) exceed its short term liabilities (A$590.3K).
Long Term Liabilities: AVE's short term assets (A$6.1M) exceed its long term liabilities (A$60.9K).
Debt to Equity History and Analysis
Debt Level: AVE is debt free.
Reducing Debt: AVE has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AVE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AVE has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 36% each year.
What is Avecho Biotechnology current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AVE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AVE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AVE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AVE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AVE's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Paul Gavin, BSc (Hons), PhD serves as Chief Executive Officer of Avecho Biotechnology Limited (formerly known as Phosphagenics Limited) since May 01, 2020 and served as its Chief Scientific Officer unt...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD352.91K) is about average for companies of similar size in the Australian market ($USD301.38K).
Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.
Experienced Management: AVE's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Experienced Board: AVE's board of directors are considered experienced (4.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.9%.
Avecho Biotechnology Limited's employee growth, exchange listings and data sources
- Name: Avecho Biotechnology Limited
- Ticker: AVE
- Exchange: ASX
- Founded: 1992
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$33.050m
- Shares outstanding: 1.84b
- Website: https://avecho.com.au
Number of Employees
- Avecho Biotechnology Limited
- 2A Westall Road
- Unit A8
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 07:01|
|End of Day Share Price||2021/10/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.